Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both sublingual and oral minoxidil at 5 mg per day increased hair density similarly in men with androgenetic alopecia over 24 weeks, but sublingual administration was associated with fewer palpitations.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study found that the nanostructured lipid carrier gel containing minoxidil showed good consistency and a prolonged drug release in vitro, suggesting potential for treating alopecia.

This study successfully developed a method to measure four flavonoids from Platycladus orientalis leaves in rat plasma, which was used in a pharmacokinetic study on healthy rats.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This study found that finasteride maintained chemical and physical stability in various excipient mixtures, which may guide the development of stable topical delivery systems.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

This study found that in male rats, hesperidin co-administration ameliorated finasteride-induced testicular toxicity by reducing oxidative stress and improving antioxidant status, sperm parameters, and enzyme activity compared to finasteride treatment alone.

This study demonstrated a method for delivering a photosensitizer, Ammi majus fructuum furocumarines, into hair follicles using calcium carbonate particles, followed by UVA irradiation, which led to significant pigment accumulation, indicating potential improvements for photochemical therapy.

This study developed and validated a UV spectrophotometric method for accurately estimating Minoxidil in tablet form, showing linearity across concentrations from 1-6µg/ml.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

This study reported that oleic acid-based nanovesicles improve follicular delivery and reduce side effects of minoxidil compared to traditional MXD lotions.

This study developed and validated a simple, cost-effective UV–Visible spectrophotometric method for estimating finasteride in pharmaceuticals, demonstrating good linearity, accuracy, precision, and sensitivity according to ICH guidelines, making it suitable for routine quality control.

This study developed a validated UV spectrophotometric method that can be used to accurately determine finasteride content in bulk and pharmaceutical formulations.

This study reported that adding the topical product CG210 to oral finasteride 1mg significantly increased hair diameter more than finasteride alone in male androgenetic alopecia patients already stabilized on finasteride treatment.

This study identified several compounds, including Pictilisib and Nimorazole, that may have higher binding affinity for SARS-CoV-2 main protease than existing inhibitors, potentially offering new treatment alternatives for Covid-19.

In this study, topical minoxidil was reported to increase fenestration in follicular capillary walls around anagen hair bulbs in male rats.

This article compares cabergoline and bromocriptine for treating hyperprolactinemic amenorrhea and reports no specific findings.

In this study, finasteride dose-dependently inhibited stress-induced increases in allopregnanolone in rats, while enhancing 20alpha-reduction of progesterone without affecting 3alpha-dihydroprogesterone or 11-deoxycorticosterone levels.

This study presents a case of treatment-resistant alopecia universalis that successfully responded to a combination of tofacitinib and oral minoxidil, highlighting a potential therapeutic approach for challenging cases of alopecia areata.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

This study established a stable cell line for CRF1 receptor screening, which can be used to develop functional cosmetics and modulators potentially affecting hair re-growth.

This review discusses the pharmacological profile of teriflunomide for treating relapsing multiple sclerosis, highlighting its safety and effectiveness in reducing relapses and slowing disability progression, though direct comparisons with other oral medications are lacking.

This study confirms that twice-daily application of 5% minoxidil solution, Carexidil®, is effective for androgenetic alopecia in both men and women, showing results after 6 months.

This study identified NM_026333 as a potential anti-aging gene that, when induced, may alleviate proton-induced aging symptoms in CF6-overexpressing and high salt-fed mice.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

This study reviewed existing literature on Androgenetic Alopecia treatments, finding that minoxidil promotes hair growth but can cause side effects due to its traditional formulations. Novel delivery systems like film-forming sprays may reduce these side effects and enhance efficacy.